1. Home
  2. peptides
Prev
AOD 9604$114.00
Next
CJC-1295 Dac$94.00
View details

Cagrilintide Acetate

(0 customer reviews)

$135.00

Cagrilintide Acetate 10 mg | 1 vial
  • Ingredient:Cagrilintide Acetate
  • Manufacturer:Dragon Pharma

$135.00

Add to cart
  • Delivery Return

    Delivery

    We ship all over Australia and New Zealand. All orders are shipped with a tracking number. Always free shipping for orders over $2000. During sale periods and promotions the delivery time may be longer than normal.

    Return

    We will accept exchanges and returns of unworn and unwashed garments within 30 days of the date of purchase (14 days during the sales period), on presentation of the original till receipt at any store where the corresponding collection is available within the country of purchase.

    Your return will usually be processed within a week to a week and a half. We’ll send you a Return Notification email to notify you once the return has been completed.
    Please allow 1-3 business days for refunds to be received to the original form of payment once the return has been processed.

    Help

    • Give us a shout if you have any other questions and/or concerns.
    • Email: sales@steroids-australia.com
    • Phone: +61 489 979 477
Category:

Guaranteed Safe Checkout

Free

Worldwide Shopping

100%

Guaranteed Satisfaction

30 Day

Guaranteed Money Back

Cagrilintide Acetate is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.

Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy.

Cagrilintide Acetate alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.